Arvinas, Inc. (ARVN): Price and Financial Metrics


Arvinas, Inc. (ARVN): $78.32

-0.33 (-0.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ARVN POWR Grades


  • ARVN scores best on the Sentiment dimension, with a Sentiment rank ahead of 55.66% of US stocks.
  • ARVN's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
  • ARVN's current lowest rank is in the Quality metric (where it is better than 10.37% of US stocks).

ARVN Stock Summary

  • ARVN's went public 2.72 years ago, making it older than only 6.72% of listed US stocks we're tracking.
  • ARVN's price/sales ratio is 188; that's higher than the P/S ratio of 97.49% of US stocks.
  • Revenue growth over the past 12 months for Arvinas Inc comes in at -53.31%, a number that bests only 6.18% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Arvinas Inc are FGEN, CUE, ACRS, XAIR, and APTX.
  • Visit ARVN's SEC page to see the company's official filings. To visit the company's web site, go to www.arvinas.com.

ARVN Price Target

For more insight on analysts targets of ARVN, see our ARVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $113.85 Average Broker Recommendation 1.35 (Strong Buy)

ARVN Stock Price Chart Interactive Chart >

Price chart for ARVN

ARVN Price/Volume Stats

Current price $78.32 52-week high $92.77
Prev. close $78.65 52-week low $19.68
Day low $77.11 Volume 170,197
Day high $79.68 Avg. volume 447,779
50-day MA $68.70 Dividend yield N/A
200-day MA $55.70 Market Cap 3.84B

Arvinas, Inc. (ARVN) Company Bio


Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.


ARVN Latest News Stream


Event/Time News Detail
Loading, please wait...

ARVN Latest Social Stream


Loading social stream, please wait...

View Full ARVN Social Stream

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

101 College Street Groundbreaking Ceremony Arvinas participates in a ceremonial groundbreaking for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven’s Downtown Crossing revitalization project. NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community par

Yahoo | June 7, 2021

Connecting The Dots: Are Pfizer And Arvinas At Work On A COVID Cure?

Photo by Naeblys/iStock via Getty Images A caution: Readers here on Seeking Alpha know me best for my many articles on Micron Technology (NASDAQ:MU) where I've been on board in various degrees for a nine-fold increase. So what's a tech nerd doing writing on pharma? My sole academic endeavor of...

Electric Phred on Seeking Alpha | May 21, 2021

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

– Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations – Aerial View Aerial view of 101 College Street in the Downtown Crossing section of New Haven, Conn. Street View Street view of 101 College Street in the Downtown Crossing section of New Haven, Conn. Courtyard View A view of the outdoor courtyard and sidewalk area adjacent to 101 College Street. NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will be leasing three of the 10 floors at 101 College Street in New Haven, Conn. Winstanley Enterprises, LLC., is the developer on this multi-tenant project. The 101 College Street...

Yahoo | May 4, 2021

Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 4, 2021

Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Last quarter we reinforced our leadership position in the targeted protein degradation space by sharing the discovery and chemical structures of ARV-110 and ARV-471 at the American Association for Cancer Research (AACR) Annual Meeting, the first such disclosure of our clinical-stage PROTAC degraders,” said John Houston, Ph.D., President and Chief Executive Officer at Arvinas. “We look forward to further demonstrating the potential of our PROTAC platform to change the lives of patients with...

Yahoo | May 4, 2021

Read More 'ARVN' Stories Here

ARVN Price Returns

1-mo 22.78%
3-mo 17.00%
6-mo 13.59%
1-year 161.07%
3-year N/A
5-year N/A
YTD -7.78%
2020 106.69%
2019 219.77%
2018 N/A
2017 N/A
2016 N/A

Continue Researching ARVN

Here are a few links from around the web to help you further your research on Arvinas Inc's stock as an investment opportunity:

Arvinas Inc (ARVN) Stock Price | Nasdaq
Arvinas Inc (ARVN) Stock Quote, History and News - Yahoo Finance
Arvinas Inc (ARVN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8701 seconds.